
BioLineRx Ltd. BLRX
$ 1.49
-1.97%
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
2.47 B |
Market Cap[1] |
$ 3.67 B |
EBITDA (LTM) |
$ -10.3 M |
P/E (LTM) |
-205.0 |
P/S (LTM) |
4282.888846 |
EPS (LTM) |
-0.01 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Merus N.V.
MRUS
|
- | - | $ 5.78 B | Nasdaq Global Select Market | ||
|
RAPT Therapeutics
RAPT
|
- | - | $ 2.36 B | Nasdaq Global Select Market | ||
|
Annexon
ANNX
|
$ 4.2 | -0.36 % | $ 651 M | Nasdaq Global Select Market | ||
|
AbbVie
ABBV
|
$ 294.72 | 0.32 % | $ 521 B | NYSE,SPB | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
$ 4.63 | 21.05 % | $ 20 M | Nasdaq Capital Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Achieve Life Sciences
ACHV
|
$ 6.78 | 0.89 % | $ 296 M | Nasdaq Capital Market | ||
|
Axon Enterprise
AXON
|
$ 316.97 | 4.77 % | $ 24.7 B | Nasdaq Global Select Market,SPB | ||
|
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | Nasdaq Global Select Market | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 62.89 | 0.18 % | $ 128 B | NYSE,SPB | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | ||
|
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | Nasdaq Global Market | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 58.59 | 4.29 % | $ 7.04 M | Nasdaq Global Select Market,SPB | ||
|
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 159.75 | 5.35 % | $ 20.9 B | Nasdaq Global Select Market,SPB | ||
|
Amgen
AMGN
|
$ 467.97 | 0.59 % | $ 252 B | Nasdaq Global Select Market,SPB | ||
|
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | Nasdaq Capital Market | ||
|
Codiak BioSciences
CDAK
|
- | -55.98 % | $ 2.15 M | Nasdaq Global Market | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
$ 248.31 | 1.17 % | $ 15.1 B | Nasdaq Global Select Market | ||
|
Johnson & Johnson
JNJ
|
$ 280.31 | -0.17 % | $ 675 B | NYSE,SPB | ||
|
Kala Pharmaceuticals
KALA
|
$ 0.17 | 0.64 % | $ 1.39 M | Nasdaq Global Select Market | ||
|
Sage Therapeutics
SAGE
|
- | - | $ 527 M | Nasdaq Global Select Market,SPB | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 1.59 | -2.76 % | $ 2.62 M | NYSE American | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 1.13 | 8.17 % | $ 260 M | NYSE American | ||
|
Paratek Pharmaceuticals
PRTK
|
- | - | $ 121 M | Nasdaq Global Market | ||
|
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | Nasdaq Global Select Market,SPB | ||
|
C4 Therapeutics
CCCC
|
$ 2.9 | -3.5 % | $ 240 M | Nasdaq Global Select Market | ||
|
Eli Lilly and Company
LLY
|
$ 1 437.4 | 0.36 % | $ 1.29 T | NYSE,SPB | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
- | -14.27 % | $ 1.7 M | Nasdaq Global Market | ||
|
Compugen Ltd.
CGEN
|
$ 2.09 | -0.24 % | $ 195 M | Nasdaq Global Market,SPB | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | Nasdaq Global Select Market | ||
|
GeoVax Labs
GOVX
|
$ 2.13 | -20.4 % | $ 2.04 M | Nasdaq Global Select Market | ||
|
Unity Biotechnology
UBX
|
- | -33.41 % | $ 3.37 M | Nasdaq Global Select Market | ||
|
MediciNova
MNOV
|
$ 1.41 | 0.36 % | $ 69.2 M | Nasdaq Global Market | ||
|
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | Nasdaq Capital Market | ||
|
Seelos Therapeutics
SEEL
|
- | -47.76 % | $ 6.27 M | Nasdaq Capital Market | ||
|
Celldex Therapeutics
CLDX
|
$ 30.18 | -1.53 % | $ 2 B | Nasdaq Global Select Market | ||
|
Moderna
MRNA
|
$ 248.62 | -0.88 % | $ 96.7 B | Nasdaq Global Select Market,SPB | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.96 | 1.41 % | $ 48.3 M | Nasdaq Capital Market | ||
|
Kiromic BioPharma
KRBP
|
- | 6.61 % | $ 3.08 M | Nasdaq Global Select Market | ||
|
Nektar Therapeutics
NKTR
|
$ 38.41 | 1.67 % | $ 648 M | Nasdaq Global Select Market,SPB | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
CorMedix
CRMD
|
$ 5.31 | -2.23 % | $ 383 K | Nasdaq Global Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 45.39 | 0.53 % | $ 4.08 B | Nasdaq Global Market,SPB | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.66 | -2.64 % | $ 1.12 B | Nasdaq Capital Market | ||
|
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | ||
|
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | ||
|
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.